Loading...

Austar Lifesciences Limited

6118.HK•HKSE
Healthcare
Medical - Devices
HK$0.68
HK$-0.03(-4.23%)

Austar Lifesciences Limited (6118.HK) Stock Overview

Explore Austar Lifesciences Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 65.3/100

Key Financials

Market Cap348.6M
P/E Ratio19.78
EPS (TTM)$0.03
ROE0.02%
Fundamental Analysis

AI Price Forecasts

1 Week$0.68
1 Month$0.60
3 Months$0.80
1 Year Target$0.37

6118.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Austar Lifesciences Limited (6118.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 43.56, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.37.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 19.78 and a market capitalization of 348.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

43.56RSI (14)
-0.01MACD
24.35ADX
Stats data is not available for 6118.HKStats details for 6118.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 6118.HKAnalyst Recommendations details for 6118.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.

CEO

Kwok Keung Ho

Employees

1,445

Headquarters

Rooms 2010-2013, Shanghai

Founded

2014

Frequently Asked Questions

;